Sichuan Biokin Pharmaceutical Co. Ltd. A
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 … Read more
Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) - Net Assets
Latest net assets as of June 2025: CN¥2.80 Billion CNY
Based on the latest financial reports, Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) has net assets worth CN¥2.80 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.18 Billion) and total liabilities (CN¥4.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.80 Billion |
| % of Total Assets | 38.95% |
| Annual Growth Rate | 127.04% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1141.15 |
Sichuan Biokin Pharmaceutical Co. Ltd. A - Net Assets Trend (2021–2024)
This chart illustrates how Sichuan Biokin Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sichuan Biokin Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual net assets of Sichuan Biokin Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.89 Billion | +2458.66% |
| 2023-12-31 | CN¥151.87 Million | -83.74% |
| 2022-12-31 | CN¥933.89 Million | +181.42% |
| 2021-12-31 | CN¥331.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sichuan Biokin Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 264453728181.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.59 Billion | 66.52% |
| Other Components | CN¥1.30 Billion | 33.48% |
| Total Equity | CN¥3.89 Billion | 100.00% |
Sichuan Biokin Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Sichuan Biokin Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dr. Ing. h.c. F. Porsche AG
PINK:DRPRF
|
$2.58 Billion |
|
Ansell Limited
PINK:ANSLF
|
$2.58 Billion |
|
Atco Ltd
PINK:ACLLF
|
$2.59 Billion |
|
Cngr Advanced Material Co Ltd
SHE:300919
|
$2.59 Billion |
|
Metaplanet Inc.
PINK:MTPLF
|
$2.58 Billion |
|
Fortress Transportation and Preferred Series B
NASDAQ:FTAIO
|
$2.58 Billion |
|
Shift4 Payments Inc 6% PRF CONVERT 01/05/2028 USD 100 - Ser A
NYSE:FOUR-PA
|
$2.57 Billion |
|
Curbline Properties Corp.
NYSE:CURB
|
$2.57 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sichuan Biokin Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 151,873,300 to 3,885,924,780, a change of 3,734,051,480 (2458.7%).
- Net income of 3,707,504,556 contributed positively to equity growth.
- Dividend payments of 38,362,941 reduced retained earnings.
- Other factors increased equity by 64,909,866.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥3.71 Billion | +95.41% |
| Dividends Paid | CN¥38.36 Million | -0.99% |
| Other Changes | CN¥64.91 Million | +1.67% |
| Total Change | CN¥- | 2458.66% |
Book Value vs Market Value Analysis
This analysis compares Sichuan Biokin Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 26.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 279.86x to 26.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥0.92 | CN¥257.33 | x |
| 2022-12-31 | CN¥2.33 | CN¥257.33 | x |
| 2023-12-31 | CN¥0.38 | CN¥257.33 | x |
| 2024-12-31 | CN¥9.69 | CN¥257.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sichuan Biokin Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 95.41%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 63.67%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.84x
- Recent ROE (95.41%) is above the historical average (-119.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -30.13% | -12.55% | 0.84x | 2.87x | CN¥-133.18 Million |
| 2022 | -30.24% | -40.15% | 0.35x | 2.13x | CN¥-375.77 Million |
| 2023 | -513.91% | -138.91% | 0.39x | 9.38x | CN¥-795.69 Million |
| 2024 | 95.41% | 63.67% | 0.82x | 1.84x | CN¥3.32 Billion |
Industry Comparison
This section compares Sichuan Biokin Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) | CN¥2.80 Billion | -30.13% | 1.57x | $2.58 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |